BR0010485A - Formulações de derivados de eritromicina de liberação prolongada - Google Patents

Formulações de derivados de eritromicina de liberação prolongada

Info

Publication number
BR0010485A
BR0010485A BR0010485-0A BR0010485A BR0010485A BR 0010485 A BR0010485 A BR 0010485A BR 0010485 A BR0010485 A BR 0010485A BR 0010485 A BR0010485 A BR 0010485A
Authority
BR
Brazil
Prior art keywords
composition
erythromycin
formulations
prolonged release
erythromycin derivative
Prior art date
Application number
BR0010485-0A
Other languages
English (en)
Inventor
Gerald F Notario
Robert N Palmer
Richard C Hom
Jie Zhang
Karen J Devcich
Laman Al-Razzak
Sheril L Cramption
Linda E Gustavson
Ho-Wah Hui
Nelly Milman
Susan J Semla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23651825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR0010485A publication Critical patent/BR0010485A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES DE DERIVADOS DE ERITROMICINA DE LIBERAçãO PROLONGADA". é revelada uma composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrintestinal. A composição compreende um derivado de eritromicina e um polímero farmaceuticamente aceitável, tal que quando ingerida oralmente, a composição induz uma C~ máx ~ estatisticamente significativamente mais baixa no plasma que uma composição de liberação imediata de derivado de eritromicina mantendo ao mesmo tempo a biodisponibilidade substancialmente equivalente àquela da composição de liberação imediata de derivado de eritromicina sob dosagem múltipla. As composições da invenção possuem um aprimorado perfil de paladar e reduzidos efeitos colaterais gastrintestinais como comparado àqueles para a composição de liberação imediata.
BR0010485-0A 1999-10-13 2000-10-13 Formulações de derivados de eritromicina de liberação prolongada BR0010485A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/416,916 US6551616B1 (en) 1997-04-11 1999-10-13 Extended release formulations of erythromycin derivatives
PCT/US2000/028407 WO2001026663A1 (en) 1999-10-13 2000-10-13 Extended release formulations of erythromycin derivatives

Publications (1)

Publication Number Publication Date
BR0010485A true BR0010485A (pt) 2002-08-20

Family

ID=23651825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010485-0A BR0010485A (pt) 1999-10-13 2000-10-13 Formulações de derivados de eritromicina de liberação prolongada

Country Status (14)

Country Link
US (3) US6551616B1 (pt)
EP (1) EP1223949A1 (pt)
KR (1) KR20020068522A (pt)
AR (1) AR026045A1 (pt)
AU (1) AU1203601A (pt)
BG (1) BG106683A (pt)
BR (1) BR0010485A (pt)
CA (1) CA2387621A1 (pt)
HU (1) HUP0203540A3 (pt)
IL (1) IL149033A0 (pt)
NO (1) NO20021747D0 (pt)
PL (1) PL354783A1 (pt)
SK (1) SK4862002A3 (pt)
WO (1) WO2001026663A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CA2405918A1 (en) * 2001-10-01 2003-04-01 Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
EP2422773A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US8758820B2 (en) * 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0417360A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
JP2007513146A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
GB0903262D0 (en) * 2009-02-26 2009-04-08 Johnson Matthey Plc Filter
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
CN102711463B (zh) * 2009-12-03 2015-05-13 Opko健康公司 超硫酸化双糖制剂
WO2018035050A1 (en) 2016-08-16 2018-02-22 Opko Pharmaceuticals, Llc Pure heptasulfated disaccharides having improved oral bioavailability
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
FI69254C (fi) 1984-02-01 1986-01-10 Lujari Instmsto Oy Anordning foer avskiljande av fasta aemnen fraon avfallsvatten
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
FR2585948B1 (fr) 1985-08-06 1988-12-16 Pf Medicament Procede de fabrication de comprimes d'indometacine
DE3613799C1 (de) * 1986-04-24 1987-09-03 Nattermann A & Cie Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln
US4808411A (en) 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JPH01308223A (ja) 1988-02-22 1989-12-12 Taisho Pharmaceut Co Ltd 均質な微細皮膜製剤の製造方法
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US4925765A (en) * 1988-12-23 1990-05-15 E. I. Du Pont De Nemours And Company Negative solid block toner
US5017383A (en) 1989-08-22 1991-05-21 Taisho Pharmaceutical Co., Ltd. Method of producing fine coated pharmaceutical preparation
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
TW271400B (pt) * 1992-07-30 1996-03-01 Pfizer
US5393765A (en) 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
KR100232297B1 (ko) 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
US5919489A (en) 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DE19706978A1 (de) 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
DE19706979A1 (de) 1997-02-21 1998-08-27 Lindopharm Gmbh Kombinationspräparat für oral applizierbare Erythromycine
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
EP0943341A1 (en) 1998-02-18 1999-09-22 Oscar Gold Procedure to prepare granulated compositions that contain erythromycin macrolides and procedure to prepare pharmaceutical compositions that contain said macrolides

Also Published As

Publication number Publication date
HUP0203540A3 (en) 2003-03-28
PL354783A1 (en) 2004-02-23
US6551616B1 (en) 2003-04-22
US20030133981A1 (en) 2003-07-17
AU1203601A (en) 2001-04-23
EP1223949A1 (en) 2002-07-24
NO20021747D0 (no) 2002-04-12
WO2001026663A1 (en) 2001-04-19
AR026045A1 (es) 2002-12-26
HUP0203540A2 (hu) 2003-02-28
SK4862002A3 (en) 2002-10-08
BG106683A (bg) 2002-12-29
KR20020068522A (ko) 2002-08-27
US20060039969A1 (en) 2006-02-23
CA2387621A1 (en) 2001-04-19
IL149033A0 (en) 2002-11-10
US6872407B2 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
BR0010485A (pt) Formulações de derivados de eritromicina de liberação prolongada
CA2285266A1 (en) Extended release formulations of erythromycin derivatives
AU2681300A (en) Solid oral dosage form containing an enhancer
AU2002243387A1 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
WO2007048219A3 (en) Sustained drug release composition
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
CA2385890A1 (en) Controlled release compositions comprising nimesulide
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
WO2002043765A3 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
BR9611802A (pt) Composições farmacêuticas
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP0966966A3 (en) Nefazodone dosage form
WO2002044324A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2004108162A3 (en) Controlled release pharmaceutical composition
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
PE20050755A1 (es) Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
DK1200106T3 (da) Præparat indeholdende Butyrospermum parkii-ekstrakter og anvendelse deraf som lægemiddel eller kosttilskud
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/7048, A61K 47/38, A61K 9/22, A61P 31/04

Ipc: A61K 31/7048 (2009.01), A61K 47/38 (2009.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 10 ( VIII ), 11 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.